Ugo D. G.
- Country
- Italy
- Department
- S.C. Oncologia Medica
Research Overview
- Palazestrant and Ribociclib versus Letrozole and Ribociclib for First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Phase 3 Study of LY4170156 (Sofetabart Mipitecan) ± Bevacizumab versus standard chemotherapy in platinum‑resistant and platinum‑sensitive ovarian cancer
- Phase 3 Randomized Study of Rinatabart Sesutecan + Bevacizumab vs Bevacizumab in Recurrent Platinum‑Sensitive Ovarian Cancer after Second‑Line Platinum Doublet
Data & Insights
Has run more than one trial at 187 of 392 partner sites.
Specializations
Gynecologic Oncology
The investigator specializes in treating advanced gynecologic malignancies, with particular focus on innovative therapies for ovarian and endometrial cancers.
- High-grade serous ovarian cancer treatment
- Recurrent endometrial cancer management
- Uterine serous carcinoma therapy
Actively explores combination treatment approaches including targeted therapies and immunotherapy regimens.
Breast Cancer
Demonstrates extensive experience in treating hormone receptor-positive breast cancer and triple-negative breast cancer.
- Metastatic breast cancer treatment
- HER2-positive breast cancer therapy
- BRCA-related breast cancers
Focuses on developing personalized treatment strategies incorporating endocrine therapy and novel therapeutic combinations.
Genitourinary Oncology
Specializes in treating complex urological cancers with expertise in both early-stage and advanced disease states.
- Muscle-invasive bladder cancer
- Metastatic renal cell carcinoma
- Castration-resistant prostate cancer
Implements multimodal treatment approaches combining systemic therapies with targeted agents.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.